DYNAMICS OF INDICATORS OF LEPTIN, ADIPONECTIN AND INTERLEUKIN-6 IN THE APPOINTMENT SARTANS, STATINS AND URSODEOXYCHOLIC ACID IN PATIENTS WITH HYPERTENSION COMBINED WITH OBESITY AND NONALCOHOLIC STEATOHEPATITIS
DOI:
https://doi.org/10.11603/1811-2471.2017.v1.i3.7820Keywords:
hypertension, obesity, nonalcoholic steatohepatitis, adiponectin, leptin, interleukin-6.Abstract
The aim was to evaluate the dynamics of clinical and laboratory parameters in patients with arterial hypertension combined with obesity and nonalcoholic steatohepatitis at combination therapy of sartans, statins and ursodeoxycholic acid (UDCA).
Materials and methods
The study involved 50 patients with stage II-III hypertension who were divided into two groups. Patients of the first group were prescribed telmisartan (20 mg), atorvastatin (20 mg) and UDCA (10 mg/kg) every day. Patients of the second group were prescribed olmesartan (10 mg), atorvastatin (20 mg) and UDCA (10 mg/kg) every day. The evaluation of clinical and hemodynamic laboratory efficiency and combinations of these drugs after 12 weeks of treatment we performed.
The results of research Appointment within 12 weeks of the combination of UDCA and atorvastatin in the treatment of olmesartan or telmisartan patients in both groups noted a significant decrease in all hemodynamic indicators, significant reduction in cholesterol levels (p<0,01), low density lipoprotein (p<0,05) and alanine aminotransferase.
Also, this drugs combination resulted in lower levels of interleukin-6 and leptin in both groups, but the changes in leptin levels; it was not statistically significant due to the large range of indicators. Noted a significant increase in adiponectin concentrations (up to 25,94±0,65 mg/ml) in the first group, indicating a direct effect of telmisartan on adiponectin levels.
Conclusions Appointment combinations sartans (telmisartan or olmesartan) in combination with atorvastatin and ursodeoxycholic acid for 12 weeks to patients with arterial hypertension combined with obesity and nonalcoholic steatohepatitis, has a positive effect on the general condition of patients by maintaining optimal blood pressure reduction, subjective complaints and improve the hemodynamics of the heart.
This combination of drugs improves the lipid spectrum of the blood (by reducing levels of total cholesterol (p<0,01) and low density lipoprotein (p<0,01)), lowers leptin and interleukin-6 (p<0,01)
Telmisartan combination of atorvastatin and ursodeoxycholic acid in patients with arterial hypertension combined with obesity and nonalcoholic steatohepatitis leads to a significant increase level of adiponectin (p<0,01).
References
Amosova, E. N. (2011). Ot lechenyya ateroskleroza k modyfykacyy prognoza: fokus na lypydosnyzhayushhuyu terapyyu. Chast I [From the treatment of atherosclerosis to the modification of the prognosis: focus on lipid-lowering therapy. Part I]. Serce i sudyny. – Heart and blood vessels, 1, 6-19 [in Ukrainian].
Gubergrycz, N.B., Lareva, N.V. (2011). Statyny v gepatologyy: «czarevna-lyagushka» yly «zhaba»? [Statins in hepatology: "princess-frog" or "toad"?]. Suchasna gastroenterologiya. – Modern Gastroenterology, 6 (62), 78-91 [in Ukrainian].
Solomenchuk, T.M., Slaba, N.A., Chngryan, G.V. et al. (2013). Efektyvnist` rozuvastatynu u hvoryh na arterial`nu gipertenziyu vysokogo kardiovaskulyarnogo ryzyku [The effectiveness of rosuvastatin in patients with hypertension high cardiovascular risk]. Liky Ukrayiny. – Medicines Ukraine, 9-10, 82-89 [in Ukrainian].
Khukhlina, O.S., Gorbatyuk, I.B. (2011). Doslidzhennya vplyvu rozuvastatynu ta mosaprydu na zminy lipidnogo spektru krovi, stupin` insulinorezystentnosti ta litogennosti zhovchi u hvory`h iz poyednanym perebigom hronichnogo nekamenevogo holecystytu iz ozhy`rinnyam ta ishemichnoyu hvoroboyu sercya [The influence of rosuvastatin and mosaprydu to changes in blood lipid spectrum, the degree of insulin resistance and litohennosti bile in patients with combined flow nekamenevoho chronic cholecystitis with obesity and coronary heart disease]. Klinichna ta eksperymental`na patologiya. – Clinical and Experimental Pathology, X, 3 (37), 143-147 [in Ukrainian].
Bablyak, S.D., Khomyn, A.M. (2008). Dosvid zastosuvannya kombinovanoyi antygipertenzyvnoyi terapiyi v zhinok pohylogo viku iz zadavnenoyu arterial`noyu gipertenziyeyu [Experience of combination antihypertensive therapy in older women with long-standing hypertension]. Medycyna transportu Ukrayiny. – Medicine of transport Ukraine, 2, 64-67 [in Ukrainian].
Neutel, J.M. (2010). Choosing among reninangiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy. Current Medical Research & Opinio, 26 (1), 213–222.
Ehorov, Y.V. (2013). Arteryal'naya hypertenzyya: evolyutsyya podkhodov k lechenyyu [Arterial hypertension: the evolution of approaches to treatment]. Zdorovya Ukrayiny. – Health of Ukraine, 1, 67-68 [in Russian].
Nakayama, S., Watada, H., Mita, T. et al. (2008). Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res., 31(1), 7-13.
Boychak, M.P. (2011). Additional effects of angiotensin II receptor antagonists in the treatment of patients with hypertension. Therapia, 54, 37-38.
Kubik, M., Chudek, J., Adamczak, M., Wiecek, A. (2012). Telmisartan improves cardiometabolic profile in obese patients with arterial hypertension. Kidney Blood Press Res., 35 (4), 281-289.
The ONTARGET investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med., 2008, 358, 1547-1559.
The TRANSCEND investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. – Lancet. – 2008. – Vol. 372. – P. 1174-1183.
Pérez-Castrillón, J.L., De Luis, D., Inglada, L. et al. (2012). Telmisartan effect's on remodelling bone markers in hypertensive patients. Nutr Hosp., 27 (1), 276-280.
Mitchenko, O.I., Romanov, V.Yu., Yanovs`ka, K.O., et al. (2012). Indeks leptyn/adyponektyn yak novyj dodatkovyj surogatnyj marker aterosklerotychnogo urazhennya [Index leptin / adiponectin as a new additional surrogate marker of atherosclerotic lesions]. Ukrayins`kyj kardiologichnyj zhurnal. – Ukrainian Journal of Cardiology, 2, 40-47 [in Ukrainian].
Drapkyna, O.M., Gaczolaeva, D.S., Yvashkyn, V.T. (2010). Nealkogol`naya zhyrovaya bolezn` pecheny kak komponent metabolycheskogo syndroma [Non-alcoholic fatty liver disease as a component of the metabolic syndrome]. Rossyjskye medycynskye vesty. – Russian medical reports, 2, 72-78 [in Russian].
Koval`, S.N., Snegurskaya, Y.A. (2011). Gormon zhyrovoj tkanyny adyponektyn i ego rol` v patogeneze metabolycheskogo syndroma i serdechno-sosudystyh zabolevanyj. Gypoadyponektynemyya kak terapevtycheskaya myshen [Adiponectin adipose tissue fat hormone and its role in the pathogenesis of metabolic syndrome and cardiovascular diseases. Hypodiponectinemia as a therapeutic target]. Zhurn. NAMN Ukrayiny. – Journal. NAMN of Ukraine., 2 (17), 174-185 [in Russian].
